Skip to main content
Interrater reliability of the new criteria for behavioral variant frontotemporal dementia
- LaMarre, Amanda K;
- Rascovsky, Katya;
- Bostrom, Alan;
- Toofanian, Parnian;
- Wilkins, Sarah;
- Sha, Sharon J;
- Perry, David C;
- Miller, Zachary A;
- Naasan, Georges;
- Laforce, Robert Jr;
- Hagen, Jayne;
- Takada, Leonel T;
- Tartaglia, Maria Carmela;
- Kang, Gail;
- Galasko, Douglas;
- Salmon, David P;
- Farias, Sarah Tomaszewski;
- Kaur, Berneet;
- Olichney, John M;
- Park, Lovingly Quitania;
- Mendez, Mario F;
- Tsai, Po-Heng;
- Teng, Edmond;
- Dickerson, Bradford Clark;
- Domoto-Reilly, Kimiko;
- McGinnis, Scott;
- Miller, Bruce L;
- Kramer, Joel H
- et al.
Published Web Location
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716343/No data is associated with this publication.
Abstract
Objective
To evaluate the interrater reliability of the new International Behavioural Variant FTD Criteria Consortium (FTDC) criteria for behavioral variant frontotemporal dementia (bvFTD).Methods
Twenty standardized clinical case modules were developed for patients with a range of neurodegenerative diagnoses, including bvFTD, primary progressive aphasia (nonfluent, semantic, and logopenic variant), Alzheimer disease, and Lewy body dementia. Eighteen blinded raters reviewed the modules and 1) rated the presence or absence of core diagnostic features for the FTDC criteria, and 2) provided an overall diagnostic rating. Interrater reliability was determined by κ statistics for multiple raters with categorical ratings.Results
The mean κ value for diagnostic agreement was 0.81 for possible bvFTD and 0.82 for probable bvFTD ("almost perfect agreement"). Interrater reliability for 4 of the 6 core features had "substantial" agreement (behavioral disinhibition, perseverative/compulsive, sympathy/empathy, hyperorality; κ = 0.61-0.80), whereas 2 had "moderate" agreement (apathy/inertia, neuropsychological; κ = 0.41-0.6). Clinician years of experience did not significantly influence rater accuracy.Conclusions
The FTDC criteria show promise for improving the diagnostic accuracy and reliability of clinicians and researchers. As disease-altering therapies are developed, accurate differential diagnosis between bvFTD and other neurodegenerative diseases will become increasingly important.Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.